Overview
- The partnership announced Wednesday will pilot Anthropic’s Claude models and Claude Science inside Novo’s research and development workflows and its software teams.
- Novo already uses Claude for administrative R&D tasks, including automating trial report generation and cutting patient documentation creation from months to minutes.
- Both companies said they will apply robust data governance and human oversight to model use, a pledge made after recent disclosures about attempts to misuse advanced models.
- Anthropic has reported that outside researchers tried to use Claude to develop biological threats, a revelation that has sharpened public and political calls for slower frontier AI development and stronger safeguards.
- If successful, the deal could shorten drug research timelines and change how medicines are discovered, but it will likely increase regulatory scrutiny and customer demand for private, tightly controlled AI deployments.